ozempic

DRUG2 trials

Sponsors

Morten Frost, Geropharm

Conditions

BioequivalenceOsteopeniaPharmacokineticsSafety Issues

Phase 1

The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture

Morten FrostOsteopenia

Start: 2021-03-24End: 2022-08-31Target: 64Updated: 2021-03-30

Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®.

CompletedNCT06497049

GeropharmBioequivalence, Pharmacokinetics, Safety Issues

Start: 2023-06-30End: 2024-05-05Updated: 2024-07-11

Related Papers

Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial.

2024-05-0349 citations